A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase Ⅲ Clinical Study to Compare the Efficacy and Safety of SYSA1901 vs Pertuzumab (Perjeta®) in the Neoadjuvant Therapy of HER2-Positive Breast Cancer
Overview
- Phase
- Phase 3
- Intervention
- SYSA1901
- Conditions
- HER2-positive Breast Cancer
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 560
- Locations
- 1
- Primary Endpoint
- Total pathologic complete response (tpCR) assessed by Independent Review Committee（IRC）
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a phase Ⅲ, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of SYSA1901 + trastuzumab + docetaxel vs. Perjeta® + trastuzumab + docetaxel in the participants with early-stage or locally advanced HER2-positive and HR-negative breast cancer with a primary tumor > 2 cm.
Detailed Description
This is a phase Ⅲ, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of SYSA1901 + trastuzumab + docetaxel vs. Perjeta® + trastuzumab + docetaxel in the patients with early-stage or locally advanced HER2-positive and HR-negative breast cancer with a primary tumor \> 2 cm. The eligible patients will be randomized to treatment group (SYSA1901 + Trastuzumab + Docetaxel) or control group (Perjeta® + Trastuzumab + Docetaxel) at 1:1 ratio. The stratification factor is disease category (early-stage vs. locally advanced). The primary endpoint is total pCR (tpCR). Secondary efficacy endpoints include breast pCR (bpCR), objective response rate (ORR)，pharmacokinetic (PK) and immunogenicity.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Voluntary agreement to provide written informed consent;
- •Age ≥ 18 years;
- •Histologically confirmed invasive breast carcinoma, and breast cancer staging \[in accordance with the American Joint Committee on Cancer (AJCC) staging system (8th edition)\]: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2-3, M0; T4, any N, M0);
- •Eastern Cooperative Oncology Group (ECOG) performance status: 0-1;
- •HER2 positive, defined as immunohistochemistry (IHC) 3+, or IHC 2+ with In Situ Hybridization (ISH) positive;
- •Estrogen receptor (ER) and progestin receptor (PR) negative; ER and PR negative is defined as \< 1% nuclear staining;
- •Agree to receive surgical treatment of breast cancer at the participating unit when the surgical criteria are met after neoadjuvant therapy;
- •Primary tumor size of \> 2 cm in diameter;
- •Left ventricular ejection fraction (LVEF)≥ 55% measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan;
- •Adequate major organ function, meeting the following criteria (have not received blood transfusion, EPO,G-CSF, other hematopoietic stimulating factors or medical supportive treatments within 14 days before the first dose of study drug): absolute neutrophil count (ANC) ≥1.5×10\^9 /L; Leukocyte count≥3.0×10\^9 /L, platelet (PLT) ≥100×10\^9 /L; hemoglobin ≥90 g/L; Serum creatinine ≤ 1.5 x the upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; total bilirubin ≤1.5×ULN; international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, or activated partial thromboplastin time (APTT) ≤1.5×ULN (not receiving anticoagulation), or patients receiving anticoagulation need to be within treatment target range and at a stable dose;
Exclusion Criteria
- •Stage IV (metastatic) breast cancer, inflammatory breast cancer, and bilateral breast cancer;
- •Previous severe allergic reactions to any drug or its components in this trial (NCI-CTCAE 5.0 grade greater than 3);
- •Patients with any other malignant tumor within 2 years (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer and other malignant tumors that have been radically removed and have not recurred);
- •Major surgery and incomplete recovery within 4 weeks prior to the first dose of study drug;
- •Patients have received other clinical trial drugs within 4 weeks before the first dose of study drug;
- •Received chemotherapy, endocrine therapy, anti-HER2 biological therapy, breast surgery or local radiotherapy for breast cancer (except for diagnostic biopsy surgery or benign breast tumor surgery);
- •History of immunodeficiency diseases, including human immunodeficiency virus (HIV) positive, active syphilis;
- •History of severe cardiovascular disease, including previous coronary artery bypass grafting or coronary stent implantation, myocardial infarction or cerebrovascular accident within 6 months, history of congestive heart failure or unstable angina pectoris, uncontrolled severe hypertension and arrhythmia requiring drug treatment;
- •Any uncontrollable complication, infection, or other condition that may affect study compliance or interfere with efficacy evaluation;
- •History of drug abuse, or alcoholism, drug addicts;
Arms & Interventions
Treatment group
SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: SYSA1901
Treatment group
SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: Trastuzumab
Treatment group
SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: Docetaxel
Control group
Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: Pertuzumab
Control group
Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: Trastuzumab
Control group
Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
Intervention: Docetaxel
Outcomes
Primary Outcomes
Total pathologic complete response (tpCR) assessed by Independent Review Committee（IRC）
Time Frame: Up to 5 months
The tpCR is defined as the histological evidence of no malignancy of lymph nodes in the regions of primary lesion and metastasis of breast cancer (i.e., ypT0/is, ypN0 in accordance with the AJCC staging system)
Secondary Outcomes
- Percentage of patients with tpCR as assessed by the investigator(Up to 5 months)
- Breast pathologic complete response (bpCR) assessed by IRC(Up to 5 months)
- Breast pathologic complete response (bpCR) assessed by the investigator(Up to 5 months)
- Percentage of patients with an objective response (BORR)(Prior to surgery)
- Incidence of adverse event(Up to approximately 30 months after randomization)
- Pharmacokinetic parameters of SYSA1901(Up to approximately 30 months after randomization)
- Immunogenicity of SYSA1901(Up to approximately 30 months after randomization)